Want to see SG:A50 full AI Analyst Report?
Top Page
Thomson Medical Group Ltd.
(SGX:A50)
Select Model
Select Model
Rating:48Neutral
Price Target:
S$0.05
▼(-21.67% Downside)
Action:Reiterated
Date:08/29/26
The score is held down primarily by deteriorating financial performance—recent revenue weakness, a swing to losses, and elevated leverage that reduces flexibility. Technicals are mildly supportive in the near term but still weaker over longer horizons, while valuation provides limited clarity due to the company being loss-making (negative P/E).
Positive Factors
Positive Cash Generation
Consistently positive operating cash flow and a FY2026 improvement in free cash flow provide internal funding capacity despite reported losses. This supports ongoing operations and investment while reducing immediate reliance on external financing, although sustainability still requires monitoring.
Negative Factors
Recent Revenue Contraction
The sharp FY2026 revenue decline interrupts the prior growth and rebound pattern, weakening visibility into the company’s near-term earnings base. Continued contraction would reduce operating leverage and make it harder for the healthcare platform to absorb fixed costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive Cash Generation
Consistently positive operating cash flow and a FY2026 improvement in free cash flow provide internal funding capacity despite reported losses. This supports ongoing operations and investment while reducing immediate reliance on external financing, although sustainability still requires monitoring.
Read all positive factors
Thomson Medical Group Ltd. (A50) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$1.24B
Dividend Yield0.73%
Average Volume (3M)886.57K
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue Growth6.44%
EPS Growth38.89%
CountrySG
Employees2,185
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding26,443,615,000
10 Day Avg. Volume951,270
30 Day Avg. Volume886,573
Financial Highlights & Ratios
PEG Ratio1.22
Price to Book (P/B)3.11
Price to Sales (P/S)3.27
P/FCF Ratio26.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
S$0.07Price Target Upside16.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)S$455.90M
Thomson Medical Group Ltd. Business Overview & Revenue Model
Company Description
Operating as an investment holding company, Thomson Medical Group Limited delivers healthcare services specifically tailored for women and children across Singapore, Malaysia, and Vietnam. Its core assets include the Thomson Medical Centre, alongs...
Thomson Medical Group Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
38
Negative
Cash Flow
64
Positive
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 420.08M | 394.66M | 351.15M | 355.77M | 333.71M |
| Gross Profit | 309.86M | 295.33M | 275.39M | 296.39M | 278.38M |
| EBITDA | 69.06M | 57.72M | 109.08M | 106.78M | 110.72M |
| Net Income | -29.70M | -47.58M | 14.16M | 36.55M | 53.76M |
Balance Sheet | |||||
| Total Assets | 1.77B | 1.78B | 1.81B | 1.45B | 1.36B |
| Cash, Cash Equivalents and Short-Term Investments | 113.08M | 124.21M | 167.28M | 286.59M | 161.59M |
| Total Debt | 1.13B | 1.12B | 1.12B | 762.79M | 642.86M |
| Total Liabilities | 1.25B | 1.24B | 1.23B | 872.34M | 756.60M |
| Stockholders Equity | 442.40M | 470.89M | 499.72M | 499.44M | 531.68M |
Cash Flow | |||||
| Free Cash Flow | 50.98M | 33.79M | 52.99M | 75.81M | 64.68M |
| Operating Cash Flow | 70.97M | 60.45M | 83.35M | 88.59M | 92.80M |
| Investing Cash Flow | -19.75M | -27.16M | -489.99M | -13.39M | -29.44M |
| Financing Cash Flow | -62.67M | -71.19M | 281.32M | 54.22M | -23.48M |
Thomson Medical Group Ltd. Technical Analysis
Negative
0.06
Price Trends
0.05
Negative
0.05
Negative
0.06
Negative
Market Momentum
>-0.01
Negative
34.29
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:A50, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.05, and above the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 34.29 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:A50.
Thomson Medical Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
SG:A50
Thomson Medical Group Ltd.
0.05
-0.01
-20.34%
SG:P8A
Cordlife Group
0.12
-0.03
-19.33%
SG:BSL
Raffles Medical Group
0.81
-0.16
-16.92%
SG:505
Asiamedic Limited
0.02
>-0.01
-27.27%
SG:5WA
OUE Lippo Healthcare Limited
0.05
0.02
75.00%
SG:TBDD
Bangkok Dusit Medical Services Public Co Ltd Shs UnSp Singapore Depositary Receipt Repr 2/1 Sh
1.49
0.03
2.05%
Thomson Medical Group Ltd. Corporate Events
Thomson Medical Details Johor Bay Plan as It Expands Regional Healthcare Network
Oct 27, 2026
Thomson Medical Group has updated shareholders on the long-delayed Johor Bay project, saying extensive planning work has been carried out and the masterplan has been refreshed to reflect newer models of care, including more outpatient and preventi...
Thomson Medical Switches to Market Cap Benchmark for Related-Party Deal Thresholds
Sep 29, 2026
Thomson Medical Group Limited has reported a negative net tangible asset position of approximately S$266 million as at 30 June 2026, prompting a reassessment of how it measures materiality thresholds for interested person transactions under SGX li...
Thomson Medical Narrows FY2026 Loss as EBITDA Climbs but Leverage Remains Elevated
Aug 28, 2026
Thomson Medical Group reported a 6.4% rise in revenue to S$420.1 million for FY2026, driven by its Singapore, Malaysia and Vietnam operations. EBITDA grew 23.2% to S$67.3 million, while loss after tax narrowed by 40.8% to S$27.8 million, signallin...
TMC Life Sciences Berhad Posts Strong Earnings and Strengthens Balance Sheet in FY2026
Aug 14, 2026
TMC Life Sciences Berhad reported a strong improvement in financial performance for the year ended 30 June 2026, with revenue rising to RM393.0 million from RM345.5 million and profit after tax surging to RM17.4 million from RM3.6 million. Earning...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.